Amphastar Pharmaceuticals (AMPH) Free Cash Flow (2013 - 2026)

Amphastar Pharmaceuticals has reported Free Cash Flow for 14 years, with the latest figure at $42.7 million in Q2 2026.

• On a quarterly basis, Free Cash Flow rose 70.75% year-over-year to $42.7 million in Q2 2026; TTM through Jun 2026 was $152.9 million, a 36.28% increase from a year earlier, with the FY2025 full-year figure at $121.2 million, down 29.66% from the prior year.
• Free Cash Flow was $42.7 million for Q2 2026 at Amphastar Pharmaceuticals, up from $38.3 million in the prior quarter.
• The five-year high for Free Cash Flow was $63.1 million in Q2 2024, with the low at -$2.6 million in Q2 2022.
• Average Free Cash Flow over 5 years is $32.5 million, with a median of $34.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow tumbled 109.75% in 2022, then soared 1879.94% in 2023.
• Over 5 years, Free Cash Flow stood at $8.9 million in 2022, then jumped by 61.75% to $14.4 million in 2023, then advanced by 15.19% to $16.6 million in 2024, then soared by 48.02% to $24.6 million in 2025, then surged by 73.77% to $42.7 million in 2026.
• The last three Free Cash Flow figures came in at $42.7 million (Q2 2026), $38.3 million (Q1 2026), and $24.6 million (Q4 2025), per Business Quant data.